Supplementary References for Table 1

Table 1. PTEN mutations in different tumor types. Mutation frequencies summarized in Table 1 are based on currently available reports cited in Supplementary Information.

Supplementary References for Table 1:

1.Steck, P. A., Pershouse, M. A., Jasser, S. A., Yung, W. K., Lin, H., Ligon, A. H. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet., 15: 356-362, 1997.

2.Wang, S. I., Puc, J., Li, J., Bruce, J. N., Cairns, P., Sidransky, D. et al. Somatic mutations of PTEN in glioblastoma multiforme. Cancer Res., 57: 4183-4186, 1997.

3.Teng, D. H., Hu, R., Lin, H., Davis, T., Iliev, D., Frye, C. et al. MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines. Cancer Res., 57: 5221-5225, 1997.

4.Liu, W., James, C. D., Frederick, L., Alderete, B. E., and Jenkins, R. B. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas. Cancer Res., 57: 5254-5257, 1997.

5.Bostrom, J., Cobbers, J. M., Wolter, M., Tabatabai, G., Weber, R. G., Lichter, P. et al. Mutation of the PTEN (MMAC1) tumor suppressor gene in a subset of glioblastomas but not in meningiomas with loss of chromosome arm 10q. Cancer Res., 58: 29-33, 1998.

6.Chiariello, E., Roz, L., Albarosa, R., Magnani, I., and Finocchiaro, G. PTEN/MMAC1 mutations in primary glioblastomas and short-term cultures of malignant gliomas. Oncogene, 16: 541-545, 1998.

7.Tohma, Y., Gratas, C., Biernat, W., Peraud, A., Fukuda, M., Yonekawa, Y. et al. PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J. Neuropathol. Exp. Neurol., 57: 684-689, 1998.

8.Zhou, X. P., Li, Y. J., Hoang-Xuan, K., Laurent-Puig, P., Mokhtari, K., Longy, M., et al. Mutational analysis of the PTEN gene in gliomas: molecular and pathological correlations. Int. J. Cancer, 84: 150-154, 1999.

9.Davies, M. P., Gibbs, F. E., Halliwell, N., Joyce, K. A., Roebuck, M. M., Rossi, M. et al. Mutation in the PTEN/MMAC1 gene in archival low grade and high grade gliomas. Br. J. Cancer, 79: 1542-1548, 1999.

10.Kato, H., Kato, S., Kumabe, T., Sonoda, Y., Yoshimoto, T., Han, S. Y. et al. Functional evaluation of p53 and PTEN gene mutations in gliomas. Clin. Cancer Res., 6: 3937-3943, 2000.

11.Kraus, J. A., Glesmann, N., Beck, M., Krex, D., Klockgether, T., Schackert, G. et al. Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J. Neurooncol., 48: 89-94, 2000.

12.Smith, J. S., Tachibana, I., Passe, S. M., Huntley, B. K., Borell, T. J., Iturria, N. et al. PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J. Natl. Cancer Inst., 93: 1246-1256, 2001.

13.Kraus, J. A., Felsberg, J., Tonn, J. C., Reifenberger, G., and Pietsch, T. Molecular genetic analysis of the TP53, PTEN, CDKN2A, EGFR, CDK4 and MDM2 tumour-associated genes in supratentorial primitive neuroectodermal tumours and glioblastomas of childhood. Neuropathol. Appl. Neurobiol., 28: 325-333, 2002.

14.Fan, X., Aalto, Y., Sanko, S. G., Knuutila, S., Klatzmann, D., and Castresana, J. S. Genetic profile, PTEN mutation and therapeutic role of PTEN in glioblastomas. Int. J. Oncol., 21: 1141-1150, 2002.

15.Kato, H., Fujimura, M., Kumabe, T., Ishioka, C., Kanamaru, R., and Yoshimoto, T. PTEN gene mutation and high MIB-1 labeling index may contribute to dissemination in patients with glioblastoma. J Clin Neurosci, 11: 37-41, 2004.

16.Fiano, V., Ghimenti, C., Imarisio, S., Silengo, L., and Schiffer, D. PAkt, cyclin D1 and p27/Kip.1 in glioblastomas with and without EGFR amplification and PTEN mutation. Anticancer Res., 24: 2643-2647, 2004.

17.Tunca, B., Bekar, A., Cecener, G., Egeli, U., Vatan, O., Tolunay, S. et al. Impact of novel PTEN mutations in Turkish patients with glioblastoma multiforme. J. Neurooncol., 82: 263-269, 2007.

18.Obata, K., Morland, S. J., Watson, R. H., Hitchcock, A., Chenevix-Trench, G., Thomas, E. J. et al. Frequent PTEN/MMAC mutations in endometrioid but not serous or mucinous epithelial ovarian tumors. Cancer Res., 58: 2095-2097, 1998.

19.Maxwell, G. L., Risinger, J. I., Hayes, K. A., Alvarez, A. A., Dodge, R. K., Barrett, J. C. et al. Racial disparity in the frequency of PTEN mutations, but not microsatellite instability, in advanced endometrial cancers. Clin. Cancer Res., 6: 2999-3005, 2000.

20.Mutter, G. L., Lin, M. C., Fitzgerald, J. T., Kum, J. B., Baak, J. P., Lees, J. A., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J. Natl. Cancer Inst., 92: 924-930, 2000.

21.Hirai, Y., Tanaka, N., Furuta, R., Kawaguchi, T., Sakamoto, M., Shirahama, S. et al. Somatic mutations of the PTEN/NMAC1 gene associated with frequent chromosomal loss detected using comparative genomic hybridization in endometrial cancer. Gynecol. Oncol., 83: 81-88, 2001.

22.Bussaglia, E., del Rio, E., Matias-Guiu, X., and Prat, J. PTEN mutations in endometrial carcinomas: a molecular and clinicopathologic analysis of 38 cases. Hum. Pathol., 31: 312-317, 2000.

23.Wappenschmidt, B., Wardelmann, E., Gehrig, A., Schondorf, T., Maass, N., Bonatz, G., Gassel, et al. PTEN mutations do not cause nuclear beta-catenin accumulation in endometrial carcinomas. Hum. Pathol., 35: 1260-1265, 2004.

24.Konopka, B., Paszko, Z., Janiec-Jankowska, A., and Goluda, M. Assessment of the quality and frequency of mutations occurrence in PTEN gene in endometrial carcinomas and hyperplasias. Cancer Lett., 178: 43-51, 2002.

25.Konopka, B., Janiec-Jankowska, A., Czapczak, D., Paszko, Z., Bidzinski, M., Olszewski, W. et al. Molecular genetic defects in endometrial carcinomas: microsatellite instability, PTEN and beta-catenin (CTNNB1) genes mutations. J. Cancer Res. Clin. Oncol., 133: 361-371, 2007.

26.Birck, A., Ahrenkiel, V., Zeuthen, J., Hou-Jensen, K., and Guldberg, P. Mutation and allelic loss of the PTEN/MMAC1 gene in primary and metastatic melanoma biopsies. J. Invest. Dermatol., 114: 277-280, 2000.

27.Reifenberger, J., Wolter, M., Bostrom, J., Buschges, R., Schulte, K. W., Megahed, M., et al. Allelic losses on chromosome arm 10q and mutation of the PTEN (MMAC1) tumour suppressor gene in primary and metastatic malignant melanomas. Virchows Arch., 436: 487-493, 2000.

28.Celebi, J. T., Shendrik, I., Silvers, D. N., and Peacocke, M. Identification of PTEN mutations in metastatic melanoma specimens. J. Med. Genet., 37: 653-657, 2000.

29.Haluska, F. G., Tsao, H., Wu, H., Haluska, F. S., Lazar, A., and Goel, V. Genetic alterations in signaling pathways in melanoma. Clin. Cancer Res., 12: 2301s-2307s, 2006.

30.Cairns, P., Okami, K., Halachmi, S., Halachmi, N., Esteller, M., Herman, J. G., et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res., 57: 4997-5000, 1997.

31.Dong, J. T., Li, C. L., Sipe, T. W., and Frierson, H. F., Jr. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin. Cancer Res., 7: 304-308, 2001.

32.Dong, J. T., Sipe, T. W., Hyytinen, E. R., Li, C. L., Heise, C., McClintock, et alr. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene, 17: 1979-1982, 1998.

33.Rhei, E., Kang, L., Bogomolniy, F., Federici, M. G., Borgen, P. I., and Boyd, J. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas. Cancer Res., 57: 3657-3659, 1997.

34.Freihoff, D., Kempe, A., Beste, B., Wappenschmidt, B., Kreyer, E., Hayashi, Y. et al. Exclusion of a major role for the PTEN tumour-suppressor gene in breast carcinomas. Br. J. Cancer, 79: 754-758, 1999.

35.Chen, S. T., Yu, S. Y., Tsai, M., Yeh, K. T., Wang, J. C., Kao, M. C., et al. Mutation analysis of the putative tumor suppression gene PTEN/MMAC1 in sporadic breast cancer. Breast Cancer Res. Treat., 55: 85-89, 1999.